Streetbeat News

Partnerships

Electronic Arts (EA) has announced the open-sourcing of IRIS, a photosensitivity analysis tool, and the pledging of four additional accessibility-related video game patents. IRIS helps identify potential photosensitivity issues in games, benefiting players with epilepsy or similar conditions. The tool is already used in EA SPORTS titles and will be expanded to more content. EA's patent pledge allows free access to patented accessibility technologies, supporting players with disabilities and promoting inclusive gaming. The patents cover systems for automated player control, adaptive tutorials, route navigation, and personalized coaching. EA's initiatives, including the accessibility portal and previous patent pledges, have been positively received by the gaming community.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 4:13 pm

AMZN

CRM

Salesforce Inc (CRM) reported an 11% YoY increase in Q3 revenue to $8.72 billion and an adjusted profit of $2.11 per share, surpassing Wall Street expectations. Shares rose by 10% following the report. Salesforce is expanding its AI partnership with Amazon.com Inc (AMZN), integrating Amazon Bedrock into its services. Salesforce's largest units saw revenue growth, and it raised its fiscal 2024 operational cash flow growth guidance from 30% to 33%. The company is also forecasting a 10% revenue increase for Q4 and an 11% YoY rise for the full fiscal year.

Portfolio Pulse from Upwallstreet

December 01, 2023 | 4:12 pm

BIDU

NVDA

SSNLF

TSM

Nvidia Corp (NVDA) stock fell nearly 3% on Thursday due to concerns over the performance of its upcoming AI chip for China, the HGX H20, which is reported to have only about 20% of the computing power of Nvidia's H100. Chinese LLM developers, including Baidu Inc (BIDU), are seeking alternatives such as Huawei's Ascend AI chips. Nvidia's next-generation GPU is expected to be produced by Taiwan Semiconductor Manufacturing Co (TSM) and potentially packaged by Samsung Electronics Co (SSNLF), which is investing in 2.5D packaging technology.

Portfolio Pulse from Anusuya Lahiri

December 01, 2023 | 1:54 pm

IDAI

Trust Stamp (NASDAQ:IDAI) reports that 40 financial institutions are now integrating its AI-Powered Orchestration Platform, with 18 new institutions starting since January 2023. The platform is designed to combat fraud while protecting customer data and privacy. Trust Stamp's President, Andrew Gowasack, expresses optimism for the company's growth and anticipates significant revenue from long-term usage starting in 2024.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:31 pm

WGS

GeneDx (NASDAQ:WGS) announced new data supporting exome sequencing over multi-gene panels for epilepsy diagnosis, to be presented at the AES annual meeting. The study of 22,500 individuals showed a 25% diagnosis rate with exome sequencing, higher than the 19% with multi-gene panels. 78% of those diagnosed had prior testing, indicating exome sequencing's superior diagnostic ability. Over half of seizure-related genes are not on many epilepsy panels. 11% of positive diagnoses from exome sequencing involved treatment-related genes. GeneDx will also present data on better insurance coverage for exome sequencing. The NSGC and AES recommend exome sequencing as a first-tier test for unexplained epilepsy. GeneDx will host a symposium at the conference discussing the benefits of exome sequencing for epilepsy patients.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:31 pm

INTC

LMT

MSFT

NVDA

Lockheed Martin (NYSE:LMT) has secured over $500 million in U.S. government army contracts in November, including a recent $199.15 million contract for industrial engineering services. The company's revenue heavily relies on U.S. defense spending, which is expected to increase annually until 2033. Lockheed Martin's partnerships with Nvidia (NASDAQ:NVDA), Microsoft (NASDAQ:MSFT), and Intel (NASDAQ:INTC) focus on advancing defense digitization through AI, cloud technologies, and 5G. While Lockheed Martin's stock trades at $447.77, above the analyst consensus target of $438.04, the company's strong contract acquisition and strategic partnerships may influence its stock performance.

Portfolio Pulse from Surbhi Jain

December 01, 2023 | 1:25 pm

LGND

Palvella Therapeutics and Ligand Pharmaceuticals (NASDAQ:LGND) have expanded their strategic partnership to accelerate Phase 3 development of QTORIN rapamycin for Microcystic Lymphatic Malformations (Microcystic LMs). Palvella received a $5 million upfront payment from Ligand, which also increased its tiered royalty on worldwide sales of QTORIN rapamycin to 8.0–9.8%. Ligand has an option to acquire a single-digit royalty on future topical products from Palvella's QTORIN platform. QTORIN rapamycin has potential to be the first FDA-approved therapy for Microcystic LMs, with over 30,000 diagnosed patients in the U.S. The FDA granted Breakthrough Therapy Designation to the drug in November 2023.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:23 pm

AAPL

GOOG

GOOGL

MSFT

Microsoft Corp. (MSFT) is planning to launch its own Xbox mobile gaming store to compete with Apple (AAPL) and Google (GOOG, GOOGL). The move follows the completion of the $69 billion Activision Blizzard acquisition. Microsoft Gaming CEO Phil Spencer is in talks with partners to launch the store, potentially in 2024, to offer more choices for game monetization on mobile devices. The European Union's Digital Markets Act, which scrutinizes app store practices and may force Apple to allow sideloading apps, could provide an opportunity for Microsoft's mobile gaming ambitions.

Portfolio Pulse from Rounak Jain

December 01, 2023 | 12:39 pm

HUBC

HUB Cyber Security Ltd (HUBC) has expanded its collaboration with Blackswan Technologies to provide Confidential Computing cybersecurity solutions to the financial sector. A recent agreement with a major European financial institution could result in HUB's revenue exceeding $25 million within 18 months. The deal includes a 3-year term with a potential 24-month extension. HUB's Chief Strategy Officer, Noah Hershcovitz, sees this as a step towards expanding their clientele and geographical reach.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 12:37 pm

NLSP

NLS Pharmaceutics has entered into an exclusive option agreement with Aexon Labs to develop and commercialize a next-generation dual orexin agonist platform. NLS Pharmaceutics must exercise this option by March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 12:33 pm